ArticleHuman vaccines & immunotherapeutics2018
Vaccination budget in Europe: an update.
Article in Human vaccines & immunotherapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Quantitative Synthesis of Factors Associated with COVID-19 Vaccine Acceptance and Vaccine Hesitancy in 185 Countries.Vaccines · 2023Article
- A review of the sustainability of vaccine funding across Europe and implications for post-COVID policymaking.Health policy (Amsterdam, Netherlands) · 2022Review
- Optimal levels of vaccination to reduce COVID-19 infected individuals and deaths: A global analysis.Environmental research · 2022Article
- Preparedness of countries to face COVID-19 pandemic crisis: Strategic positioning and factors supporting effective strategies of prevention of pandemic threats.Environmental research · 2022Article
- Article
- Attitude towards Vaccination among Health Science Students before the COVID-19 Pandemic.Vaccines · 2021Article
- Who Guides Vaccination in the Portuguese Press? An Analysis of Information Sources.International journal of environmental research and public health · 2021Article
- New paths for sustainable solutions to tackle global and emerging infectious threats.Biologicals : journal of the International Association of Biological Standardization · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunization has been shown to be the most effective disease prevention measure of all time, apart from water purification. However, vaccination programs remain highly vulnerable to budget cuts as their benefits may not be immediately and fully identifiable. Therefore, monitoring of healthcare expenditures allocated to prevention and vaccination is critical. This letter updates our previous observation of expenditure for prevention and vaccination programs in eight European countries by adding data from 2014, where available. Prevention and vaccines still entail a relatively low level of investment in European countries. Less than 0.5% of GDP is allocated to disease prevention programs and vaccine expenditure fall below 0.5% of healthcare spending in many of the countries. An adequate level of resources needs to be allocated to ensure efficient and sustainable vaccination programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.